



ORIGINAL ARTICLE

## Experimental infection of sheep with *Bovine leukemia virus* (BLV): Minimum dose of BLV-FLK cells and cell-free BLV and neutralization activity of natural antibodies



Natalia Gabriela Porta<sup>a,b</sup>, Irene Alvarez<sup>a,b,\*</sup>, Guillermo Suarez Archilla<sup>c</sup>, Vanesa Ruiz<sup>a,b</sup>, Alejandro Abdala<sup>c</sup>, Karina Trono<sup>a,b</sup>

<sup>a</sup> Instituto Nacional de Tecnología Agropecuaria (INTA) – Instituto de Virología, Centro de Investigaciones en Ciencias Veterinarias y Agronómicas, Nicolas Repetto y de los Reseros s/n (1686), Hurlingham, Buenos Aires, Argentina

<sup>b</sup> Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Godoy Cruz 2290 (C1425FQB), CABA, Argentina

<sup>c</sup> Instituto Nacional de Tecnología Agropecuaria (INTA) – Laboratorio de Sanidad Animal, Estación Experimental Agropecuaria Rafaela, Ruta 34 Km 227 (2300) Rafaela, Santa Fe, Argentina

Received 23 July 2018; accepted 8 January 2019

Available online 22 April 2019

### KEYWORDS

Bovine leukemia virus;  
Animal model;  
Experimental infection;  
Sheep;  
FLK-BLV cells

**Abstract** *Bovine leukemia virus* (BLV) is an important cattle pathogen that causes major economic losses worldwide, especially in dairy farms. The use of animal models provides valuable insight into the pathogenesis of viral infections. Experimental infections of sheep have been conducted using blood from BLV-infected cattle, infectious BLV molecular clones or tumor-derived cells. The Fetal Lamb Kidney cell line, persistently infected with BLV (FLK-BLV), is one of the most commonly used long-term culture available for the permanent production of virus. FLK-BLV cells or the viral particles obtained from the cell-free culture supernatant could be used as a source of provirus or virus to experimentally infect sheep. In this report, we aimed to determine the minimum amount of FLK-BLV cells or cell-free supernatant containing BLV needed to produce infection in sheep. We also evaluated the amount of antibodies obtained from a naturally-infected cow required to neutralize this infection. We observed that both sheep experimentally inoculated with 5000 FLK-BLV cells became infected, as well as one of the sheep receiving 500 FLK-BLV cells. None of the animals inoculated with 50 FLK-BLV cells showed evidence of infection. The cell-free FLK-BLV supernatant proved to be infective in sheep up to a 1:1000 dilution. Specific BLV antibodies showed neutralizing activity as none of the sheep became infected. Conversely, the animals receiving a BLV-negative serum showed signs of BLV infection. These results contribute to the optimization of a sheep bioassay which could be useful to further characterize BLV infection.

© 2019 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author.

E-mail address: [alvarez.irene@inta.gob.ar](mailto:alvarez.irene@inta.gob.ar) (I. Alvarez).

<https://doi.org/10.1016/j.ram.2019.01.004>

0325-7541/© 2019 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**PALABRAS CLAVE**

Virus de la leucemia bovina;  
 Modelo animal;  
 Infección experimental;  
 Ovino;  
 Células FLK-BLV

### Infección experimental en ovinos con el virus de leucosis bovina: dosis mínima de células BLV-FLK y virus libre de células, y actividad neutralizante de anticuerpos naturales

**Resumen** El virus de la leucosis bovina (*bovine leukemia virus* [BLV]) es un importante agente patógeno del ganado que causa importantes pérdidas económicas en todo el mundo, especialmente en los rodeos lecheros. El uso de modelos animales proporciona información valiosa sobre la patogénesis de las infecciones virales. Se realizaron infecciones experimentales en ovejas usando sangre de bovinos infectados con BLV, clones moleculares de BLV infecciosos o células derivadas de tumores. La línea celular Fetal Lamb Kidney, persistentemente infectada con el BLV (FLK-BLV), es uno de los cultivos a largo plazo más utilizados para la producción permanente de virus. Las células FLK-BLV o las partículas virales obtenidas del sobrenadante del cultivo libre de células podrían usarse como fuente de provirus o de virus para infectar experimentalmente ovejas. En este trabajo, nuestro objetivo fue determinar la cantidad mínima de células FLK-BLV o de sobrenadante libre de células que contiene BLV necesaria para producir infección en ovejas. También evaluamos la cantidad de anticuerpos bovinos anti-BLV necesaria para neutralizar la infección. Observamos que las dos ovejas inoculadas experimentalmente con 5000 células FLK-BLV se infectaron, y que una de las dos ovejas que recibieron 500 células FLK-BLV se infectó. Ninguno de los animales inoculados con 50 células FLK-BLV mostró evidencia de infección. El sobrenadante FLK-BLV libre de células demostró ser infectivo en ovejas hasta la dilución 1:1000. Los anticuerpos BLV específicos mostraron actividad neutralizante, ya que ninguna de las ovejas se infectó. Por el contrario, los animales que recibieron un suero BLV negativo mostraron signos de infección por BLV. Estos resultados contribuyen a la optimización de un bioensayo en ovejas útil para caracterizar la infección por BLV.

© 2019 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

*Bovine leukemia virus* (BLV) is a retrovirus that belongs to the *Deltaretrovirus* genus and the causative agent of enzootic bovine leukosis (EBL) in cattle and water buffaloes, their natural hosts<sup>2</sup>. The infection is distributed worldwide and the individual prevalence levels of infection vary among and within countries. In the European Union, measures of control and eradication were successful in most Western European countries<sup>1,22,25</sup>. Something similar occurred in New Zealand and Australia, which are BLV-free since 2008 and 2013 respectively<sup>12</sup>. In the Americas, there are different levels of BLV prevalence; in the case of Argentina, more than 30% of cattle and over 80% of dairy farms are infected<sup>32</sup> with an individual endemicity higher than 80% in areas of intense production<sup>19</sup>. BLV infection is a serious concern since it causes major economic losses in the dairy productive system and in international trade<sup>9,30,32</sup>.

The virus can infect different cells of the immune system but has a preferential tropism for B lymphocytes. Therefore, it is a blood borne pathogen as *Human T-lymphotropic virus 1* and 2 (HTLV-I and HTLV-II)<sup>2,31</sup>, pathogens from the same viral family with genetic and antigenic similarities. Active viral expression occurs during the first stages of the infection, after which the virus remains in a silent state in the infected host, permanently integrated into the cell genome as provirus DNA<sup>2,13</sup>. This produces a persistent immune response in the host without evidence of active viral circulation.

BLV has an intense transmission dynamics. All practices carried out without blood transmission control, such as blood extraction, vaccination, castration, dehorning, injection of medications, rectal palpation, tattooing, etc., are routes of potential infection, and animals with higher levels of provirus in blood are those that represent a higher risk for transmission<sup>8,21</sup>.

Most of the infected animals are asymptomatic carriers since they do not exhibit clinical changes and their leukocyte count remains normal. Between 20 and 30% of infected animals develop persistent lymphocytosis (PL)<sup>5,6</sup>, which is characterized by a permanent and stable increase in the number of circulating peripheral CD4 + IgM + B cells. These animals do not show clinical symptoms, but an elevated white blood cell count can be observed at the hematological level<sup>37</sup>. Of all the infected animals, only 1–5% of them develop fatal lymphoma. The animals develop tumors of the lymphatic system by proliferation of B-cells, mostly affecting adult cattle (1–8 years old)<sup>7</sup>.

Cattle and water buffaloes are the natural hosts of BLV, but there are some species that can be experimentally infected with different clinical, hematological and immunological manifestations. The use of animal models is very important as they allow to study the different stages of viral infection along with the progression of the disease, as well as the characterization of samples for their infectivity, protective potential, among others. In rabbits, the infection is in most cases evidenced by the manifestation of circulating specific antibodies and the presence of the

BLV genome. In some rabbits, a decreased T-cell responsiveness to phytolectin stimulation and signs of clinical disease, such as conjunctivitis, rhinitis, severe weight loss and unexpected death, can be also observed<sup>28,39</sup>. In rats and swine, the experimental infection only provokes the presence of anti-BLV antibodies as the virus does not produce pathogenic effects<sup>3,20</sup>. In chickens, anti-BLV antibodies can be found in all experimentally inoculated animals<sup>23</sup>, but only a small proportion of them develop leukemia<sup>4</sup>. Goats develop persistent anti-BLV antibodies and are very resistant to tumor development, although after a long period of time (8 years), death by lymphoma can be observed in some cases<sup>20,26</sup>.

Among the previously described animal models, sheep particularly exhibit interesting biological features for evaluating BLV pathogenesis and also for diagnostic purposes. In fact, conversely to other animal models, most of the sheep infected with BLV develop tumors typical of the disease. Moreover, sheep usually display lymphosarcoma symptoms faster (2.5 years after BLV infection) than the natural hosts<sup>20,26</sup>. Moreover, most of the experimentally-inoculated sheep develop persistent B-cell lymphocytosis after 1.5 years<sup>11</sup>. BLV experimental infection of sheep has been successfully performed using blood from BLV-infected cattle, *in vitro* produced BLV infectious molecular clones or cells derived from tumors of infected cattle<sup>20,24,27,29</sup>. Although some cell cultures derived from different animal species are permissive to BLV, infections are difficult to perform as they produce limited quantities of virus and large amounts of cellular debris<sup>14,33</sup>. The Fetal Lamb Kidney cell line persistently infected with BLV (FLK-BLV), established by Van der Maaten and Miller<sup>33</sup>, is one of the most commonly used long-term culture available for the permanent production of virus. FLK-BLV cells or the viral particles obtained from the cell-free culture supernatant (cell-free BLV) could be used as a source of virus to experimentally infect sheep and other species<sup>39</sup>. Previous reports have focused the use of the sheep model on the study of BLV pathogenesis, the process of leukemogenesis, potential treatments to eliminate tumors, molecular genetics and epigenetic modulation of viral expression, also the association with HTLV<sup>16,17</sup>. In this context, no information was found in the literature regarding the minimum infectious dose required to establish the infection in sheep using cell-free FLK supernatant or FLK-BLV viable cells.

The aim of the present study was to determine the effect of known amounts of FLK-BLV cells or cell-free supernatant obtained from FLK-BLV cultures in sheep, and to evaluate the amount of serum antibodies derived from a naturally-infected cow required to neutralize BLV infection.

## Materials and methods

### FLK-BLV cell culture

The FLK-BLV cell line was generously provided by Dr. Luc Willems from the University of Liège, Belgium. The FLK-BLV cell line grows as a monolayer and has 4–7 copies of integrated proviral DNA and constantly secretes viral particles into the supernatant without any cytopathogenic effect, which allows to obtain large quantities of virus with a small amount of cellular debris. The FLK-BLV cells were cultured

in RPMI 1640 medium (Corning, NY, USA) supplemented with 5% of inactivated fetal bovine serum (FBS, Internegocios, Buenos Aires, Argentina) until the formation of a confluent monolayer. The medium was then replaced with RPMI medium supplemented with 1% FBS to reduce the amount of debris, and cultured for 48 h. The cell-free supernatant containing infectious BLV (cell-free BLV) was harvested, clarified by centrifugation at 3,000 rpm for 15 min and stored at  $-65 \pm 10^\circ\text{C}$  until use. Cells were harvested by trypsinization, washed 3 times with PBS and resuspended in RPMI medium. Viable cells were counted by the trypan blue exclusion method. BLV virus (FLK-BLV supernatant) and infected cells (FLK-BLV cells) were used as inoculums for infection in lambs.

### Experimental sheep

All experiments with animals were performed according to the guide on the care and use of laboratory animals of the National Institutes of Health<sup>10</sup>. The procedures followed for handling of animals, extraction and handling of samples were those of the guidelines described in the Manual of the Institutional Committee for Care and Use of Experimental Animals of the National Institute of Agricultural Technology (CICUAE-INTA). Twenty-eight 3–6 month-old BLV-free lambs (Pampinta breed) were used. Lambs were kept together in a natural grazing system until the end of the study, when they were euthanized.

### Experimental inoculations of sheep

#### Assay A: BLV-FLK cells and cell-free BLV reducing amounts

To determine the minimum amount of BLV-FLK cells or cell-free BLV required to infect sheep, 16 lambs were divided into 8 groups ( $n=2$  per group) and experimentally inoculated with different doses of FLK-BLV cells and cell-free BLV (Table 1). These inocula were obtained by serial dilutions in RPMI medium (Corning). All inocula were analyzed by nested PCR (nPCR) and retrotranscriptase-nested PCR (RT-nPCR) that amplifies a fragment of the BLV TAX gene (described in Nucleic acid extraction and amplification section) to detect the provirus and the virus, respectively<sup>38</sup>.

Animals were subcutaneously inoculated in the armpit with 5 ml of each inoculum. Whole blood samples with EDTA anticoagulant were taken by venous puncture of the jugular the day of the experimental infection, and 30 and 60 days post-infection (dpi). Plasma and buffy coat were obtained by centrifugation at 2500 rpm for 15 min and stored at  $-20^\circ\text{C}$  until analyzed. All inocula were analyzed by nPCR and RT-nPCR.

#### Assay B: neutralization assay with antibodies against BLV

In order to evaluate the neutralization of BLV infection with antibodies present in serum of naturally infected cattle, 6 lambs were divided into 3 groups ( $n=2$  per group) and inoculated with cell-free BLV diluted 1:10, previously incubated with different amounts of a BLV-positive serum (Groups 9–11, Table 2). The BLV-positive serum had a titer of antibodies of 1/128 determined by ELISA as described in "Detection of BLV antibodies" section. As a positive control, 6 lambs

**Table 1** Inocula used in assay A: BLV-FLK cells and cell-free BLV reducing amounts (minimum infectious dose assay)

Group	Inoculum (5 ml)	Concentration/Dilution <sup>a</sup>	Provirus (nPCR)	Viral transcripts (RT-nPCR)
1	FLK-BLV cells	5000 cells	+	+
2	FLK-BLV cells	50 cells	—	+
3	FLK-BLV cells	50 cells	—	+
4	Cell-free BLV	1:10	+	+
5	Cell-free BLV	1:100	—	+
6	Cell-free BLV	1:1000	—	+
7	Cell-free BLV	1:5000	—	—
8	Cell-free BLV	1:10000	—	—

<sup>a</sup> Number of cells or dilution of virus in RPMI medium in 5 ml of inoculum.

**Table 2** Inocula used in assay B: neutralization assay with antibodies against BLV

Group	Inoculum (5 ml)		Relation <sup>a</sup>	Provirus (nPCR)	Viral transcripts (RT-nPCR)
	Source of virus	Bovine serum			
9	Cell-free BLV 1:10	Positive serum	1:1	+	+
10	Cell-free BLV 1:10	Positive serum	1:2	+	+
11	Cell-free BLV 1:10	Positive serum	1:4	+	+
12	Cell-free BLV 1:10	Negativeserum	1:1	+	+
13	Cell-free BLV 1:10	Negativeserum	1:2	+	+
14	Cell-free BLV 1:10	Negativeserum	1:4	+	+

<sup>a</sup> Relation in volume cell-free BLV: bovine serum.

were divided into 3 groups (n = 2 per group) and inoculated under the same conditions but with cell-free BLV diluted 1:10, previously incubated with BLV-negative serum (Groups 12–14, Table 2). Animals were subcutaneously inoculated in the armpit with 5 ml of each inoculum. Whole blood samples with EDTA anticoagulant were taken by venous puncture of the jugular the day of the experimental infection, and 30 and 60 days post-infection (dpi). Plasma and buffy coat were obtained as explained above and stored at  $-20^{\circ}\text{C}$  until analyzed. All inocula were analyzed by nPCR and RT-nPCR.

### Detection of BLV antibodies

For the detection of BLV antibodies, an in-house ELISA test against BLV was performed (ELISA LKF) according to Trono et al.<sup>32</sup> Briefly, ELISA plates were coated with complete BLV antigens concentrated from FLK-BLV cells by centrifugation on a discontinuous sucrose gradient. The plasma samples previously diluted 1/40 were dispensed into wells in duplicates. After incubation and washing, anti-bovine IgG peroxidase conjugated was added to each well. The presence of a secondary antibody was revealed with 3,3',5,5'-tetramethylbenzidine and  $\text{H}_2\text{O}_2$ . Reaction was stopped using  $\text{H}_2\text{SO}_4$  and the absorbance was read at 450 nm. Normalized results were obtained as a sample-to-positive ratio. A weak positive control serum was used to calculate the ratio; its reactivity was set to 100% and all tested samples were referred to it and a cut-off level of 25% was established<sup>32</sup>.

### Nucleic acid extraction and amplification

Total RNA from inocula and whole blood samples was extracted using the High Pure RNA Purification Kit (Roche, Penzberg, Germany), according to the manufacturer's instructions. Extracted RNA was treated with DNases prior to reverse transcription to eliminate DNA contamination. Reverse transcription was carried out with  $0.02\ \mu\text{g}/\mu\text{l}$  of random hexamers (PROMEGA, Fitchburg, WI, USA) and  $2.4\ \text{U}/\mu\text{l}$  of M-MLV (PROMEGA). The cycling conditions of the RT-PCR were: 1 cycle at  $42^{\circ}\text{C}$  for 60 min and 1 cycle at  $95^{\circ}\text{C}$  for 5 min. Total genomic DNA was extracted using the High Pure PCR Template Preparation Kit (Roche) according to the manufacturer's instructions.

Partial amplification of the *tax* gene by nPCR was performed according to Wu et al.<sup>38</sup>, using cDNA and DNA samples as template. Primers TAX7781F (5'-CAGACACCAGGGGA-GCCATA-3') and 8083R (5'-CTGCTAGCAACCAATTCGG-A-3') were used in the first round, and primers TAX7802F (5'-AGCCATACGTTATCTCTCCA-3') and TAX8062R (5'-CAG-GTTAGCGTAGGGTCATG-3') in the second round. Positive and negative controls were included in each run. RNA samples without reverse transcription were analyzed to exclude the presence of genomic DNA in RNA samples. The expected size of the amplified product, 279 bp, was confirmed by fluorescent nucleic acid gel staining (GelRed, Biotium, CA, USA). The estimated detection limit of the reaction is about one infected cell in 10000 non-infected cells.

**Table 3** Detection of antibodies and proviral DNA at different times post-infection in lambs used in assay A (BLV-FLK cells and cell-free BLV reducing amounts)

Group	Inoculum (5 ml)	T0		T30		T60	
		Antibodies (ELISA)	Provirus (nPCR)	Antibodies (ELISA)	Provirus (nPCR)	Antibodies (ELISA)	Provirus (nPCR)
1	5000 FLK-BLV cells	–	–	–	–	–	+
2	500 FLK-BLV cells	–	–	–	+	+	+
3	50 FLK-BLV cells	–	–	–	–	–	–
4	Cell-free BLV 1/10	–	–	+	+	+	+
5	Cell-free BLV 1/100	–	–	+	+	+	+
6	Cell-free BLV 1/1000	–	–	–	+	+	+
7	Cell-free BLV 1/5000	–	–	–	–	–	–
8	Cell-free BLV 1/10000	–	–	–	–	–	–

(–) Negative, (+) positive.

## Results

### Proviral DNA and viral transcripts in the inoculation material

BLV provirus was detected by nPCR in the cell-derived inoculum containing 5000 FLK-BLV cells (Group 1, Table 1) and in the cell-free BLV diluted 1:10 (Group 4, Table 1). Viral BLV RNA was detected in the FLK-BLV cell preparations and in the dilutions 1:10 to 1:1000 of cell-free BLV (Groups 1–6, Table 1). Proviral DNA and viral BLV RNA were detected in all inocula of the neutralization assay (Groups 9–14, Table 2).

### Sheep infectivity

The presence of BLV-specific antibodies in the plasma of the inoculated animals, along with the detection of circulating BLV proviral DNA, were considered indicators of infection in lambs.

Both lambs inoculated experimentally with 5000 FLK-BLV cells showed evidence of infection (2/2), with detection of provirus and antibodies at T60 post-infection. With 500 FLK-BLV cells, only one of two sheep (1/2) became infected, and none of the sheep showed evidence of infection (0/2) with 50 FLK-BLV cells at the end of the trial. The cell-free BLV was infective down to 1:1000 dilution (2/2) (Table 3).

In the neutralization assay (Table 4), BLV positive serum showed a neutralization activity when it was previously incubated with cell-free BLV, as no sheep showed evidence of infection. As positive controls, the lambs inoculated with cell-free BLV when previously incubated with negative serum in relation showed evidence of infection 1:1 (2/2), 1:2 (2/2) and in 1:4 (1/2), with delayed detection.

## Discussion

FLK-BLV cells are a persistently infected cell line, with the integrated proviral BLV genome, which secretes viral particles into the supernatant with minimum cell debris. Previous studies have shown that this cell line is a good choice for experimental infection assays. However, the earlier reported articles showed poor details about the amounts and/or dilutions used for inoculation, regarding starting materials, viable cells or cell-free supernatants<sup>19,26</sup>. Thus, in the present study, cell-free BLV and FLK-BLV cells were used as source of virus and provirus, respectively, in different amounts.

Previous results from our laboratory have shown that the cell culture supernatant contains the maximum concentration of BLV particles 48 h after the monolayer has reached 100% confluence. Afterwards, the concentration decreases as the particles begin to degrade. A semiquantification using serial dilutions of different FLK-BLV cell supernatants up to the dilution 1:1000 sowed to be positive by RT-PCR (data not shown). Consequently, although the exact number of viral particles used in the inocula could not be estimated since *in vitro* viral titration assays are not available, the protocol for collecting FLK-BLV supernatant used in this study has been previously optimized by our group to obtain the maximum amount of viral particles.

The presence of BLV-specific antibodies in the plasma of inoculated lambs, along with the detection of BLV proviral DNA, indicates that our experimental approaches based on FLK-BLV cells or cell-free BLV were successful in establishing the infection with the virus in lambs. As expected, the dose response effect observed showed a reduction in infectivity for both initial materials at higher dilutions. The presence of proviral DNA in the absence of antibodies in the 500 FLK cell inoculum suggests that as template. In this sense, a



**Table 4** Detection of antibodies and proviral DNA at different times post-infection in lambs used in assay B (neutralization assay with antibodies against BLV)

Group	Inoculum	T0		T30		T60	
		Antibodies (ELISA)	Provirus (nPCR)	Antibodies (ELISA)	Provirus (nPCR)	Antibodies (ELISA)	Provirus (nPCR)
9	Cell-free BLV 1:10 + BLV positive	–	–	–	–	–	–
	Serum (+) 1:1	–	–	–	–	–	–
10	Cell-free BLV 1:10 + BLV positive	–	–	–	–	–	–
	Serum (+) 1:2	–	–	–	–	–	–
11	Cell-free BLV 1:10 + BLV positive	–	–	–	–	–	–
	Serum (+) 1:4	–	–	–	–	–	–
12	Cell-free BLV 1:10 + Serum (–) 1:1	–	–	+	+	+	+
		–	–	+	+	+	+
13	Cell-free BLV 1:10 + Serum (–) 1:2	–	–	+	+	+	+
		–	–	–	+	+	+
14	Cell-free BLV 1:10 + Serum (–) 1:4	–	–	–	+	+	+
		–	–	–	–	–	–

(–) Negative, (+) positive.

syncytium assay was used in the past for the detection of neutralizing antibodies using the CC81 cell line as indicator culture and the FLK cell line as effector culture, both in the presence of bovine or sheep serum that provokes syncytium inhibition in the CC81 culture in the case of neutralization activity<sup>15</sup>. This approach was not reproducible in our hands; nevertheless, we took great care in assaying multiple variables (data not shown).

Without an *in vitro* viral titration system and an *in vitro* assay for the detection of the neutralizing activity, and with the need to find a way to proceed in future experiments, we decided to advance with the previously reported *in vivo* assays using sheep. Even if the bovine is the natural host of BLV infection, this species is not the choice for characterization assays such as viral titration or neutralizing antibody detection. Neither is the choice for reproducing the disease, as the progression of infection is slow and only a small percentage of the infected animals develop fatal lymphoma after long subclinical periods. Experimental transmissions have been reported in many species with different clinical, hematological and immunological manifestations. In this respect, the sheep model has proven to be very useful in terms of obtaining information regarding immunity, viral persistence and pathogenesis. The asymptomatic period in sheep is much shorter than in cattle, with 100% of the experimentally-infected sheep developing persistent lymphocytosis and most of them progressing to the development of lymphosarcomas around 18 months post-infection. This model has been widely used not only for the analysis of natural samples but also to test the infectivity and pathogenesis of BLV molecular clones<sup>34–36</sup>. Furthermore, considering the close proximity of BLV with HTLV I and HTLV II, the sheep model was used for experimental treatments<sup>16,17</sup>.

The results presented in this work contribute to the optimization of a sheep bioassay used to further characterize the BLV infection. Particularly, the aim of this work was to determine the minimum number of FLK-BLV cells or cell-free BLV necessary to induce infection in sheep and to determine the capacity of antibodies of naturally infected bovines to

neutralize the experimental infection. This approach can be useful as it can be used in a wide range of experiments such as testing infectivity and/or the protective potential of different samples, as well as for the study of viral pathogenesis. In fact, we are currently using this approach for the analysis of the BLV-inactivating potential of heat treatments of milk and colostrum<sup>18</sup>.

The minimum infectious dose is the minimum estimated number of organisms required to produce infection in animals exposed by a given route. In the assay done in this work, we were able to determine the minimum infectious dose of provirus and virus using both FLK-BLV cells and cell-free BLV. In both cases, as the inocula were more diluted, the time of appearance of evidence of infection was longer, and the first indication of this was the detection of proviral BLV genome by nPCR and later the detection of specific antibodies against BLV by ELISA.

The results of the neutralization assay indicate that the serum of a BLV-free animal did not interfere with the infection process. The exception was the last inoculum with the highest amount of serum that suggests unspecific serum toxicity. We conclude that the assay should not be performed at 1:4 or higher proportions, as in the case of a BLV-infected animal, it would not be possible to state if the result is a consequence of the presence of specific antibodies or of the unspecific effect of the serum itself. When BLV-positive serum (titer 1/128) was added, all the proportions were capable of protecting the lambs against the virus.

This work allowed us to progress toward the setup of feasible assays to detect infectivity and neutralizing antibodies in addition to the previously reported syncytium assay which has shown to be not easy to perform, insidious to read and even difficult to reproduce. The sheep bioassay is important for future experiments and projects in our research group that needs to characterize and state parameters derived from natural and/or experimental infections. Prior to this work, we performed the experimental inoculations using the complete product of the trypsinization of a T25 flask

containing a confluent monolayer of FLK-BLV cells (cells and supernatant); now, we know the limit of infection of both cell-free BLV and viable FLK-BLV cells. Together with the positive detection of neutralizing activity, we are ready to progress toward experiments that can make use of this helpful tool.

### Conflict of interest

The authors declare that they have no conflicts of interest.

### Acknowledgements

This work was financially supported by Asociación Cooperadora de INTA Rafaela, project FONCYT PICT No. 2013-0929, project INTA PNSA-1115054 and extrapresupuestary funds from specialized technical services of the Laboratorio de Virus Adventicios (INTA) administered by Fundacion Argentina. Porta N, Alvarez I, Ruiz V and Trono K were also supported by Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET).

### References

1. Acaite J, Tamosiunas V, Lukauskas K, Milius J, Pieskus J. The eradication experience of enzootic bovine leukosis from Lithuania. *Prev Vet Med.* 2007;82:83–9.
2. Aida Y, Murakami H, Takahashi M, Takeshima S-N. Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus. *Front Microbiol.* 2013;4:1–11.
3. Altanero V, Portetelle D, Kettmann R, Altaner C. Infection of rats with bovine leukaemia virus: establishment of a virus-producing rat cell line. *J Gen Virol.* 1989;70:1929–32.
4. Altanero V, Ban J, Kettmann R, Altaner C. Induction of leukemia in chicken by bovine leukemia virus due to insertional mutagenesis. *Arch Geschwulstforsch.* 1990;60:89–96.
5. Alvarez I, Gutiérrez G, Gammella M, Martínez C, Politzki R, González C, Caviglia L, Carignano H, Fondevila N, Poli M, Trono K. Evaluation of total white blood cell count as a marker for proviral load of bovine leukemia virus in dairy cattle from herds with a high seroprevalence of antibodies against bovine leukemia virus. *Am J Vet Res.* 2013;74:744–9.
6. Barez P-Y, de Brogniez A, Carpentier A, Gazon H, Gillet N, Gutiérrez G, Hamaïdia M, Jacques J-R, Perike S, Neelature Sriramareddy S, Renotte N, Staumont B, Reichert M, Trono K, Willems L. Recent advances in BLV research. *Viruses.* 2015;7:6080–8.
7. Burny A, Cleuter Y, Kettmann R, Mammerickx M, Marbaix G, Portetelle D, Van Den Broeke A, Willems L, Thomas R. Bovine leukaemia: facts and hypotheses derived from the study of an infectious cancer. *Vet Microbiol.* 1988;17:197–218.
8. Buxton BA, Schultz RD. Factors affecting the infectivity of lymphocytes from cattle with bovine leukosis virus. *Can J Comp Med Rev Can Med Comp.* 1984;48:365–9.
9. Castellano A, Goizueta M. Valor agregado institucional: captación de valor económico de innovaciones tecnológicas; 2014. Disponible en: [https://inta.gov.ar/sites/default/files/script-tmp-inta\\_captacion\\_valor\\_economico\\_de\\_innovaciones\\_tecnol.pdf](https://inta.gov.ar/sites/default/files/script-tmp-inta_captacion_valor_economico_de_innovaciones_tecnol.pdf)
10. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide laboratory for the care and use of animals. 8th ed; 2011. Available from: <https://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-use-of-laboratory-animals.pdf>
11. Djalali S, Parodi AL, Levy D, Cockerell GL. Development of leukemia and lymphosarcoma induced by bovine leukemia virus in sheep: a hematopathological study. *Leukemia.* 1987;1:777–81.
12. European Food Safety Authority Panel on Animal Health and Welfare. Scientific opinion on Enzootic bovine leukosis. EFSA J. 2015;13:4188. Available from: <http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.4188/epdf>
13. Florins A, Gillet N, Asquith B, Boxus M, Burteau C, Twizere J-C, Urbain P, Vandermeers F, Debacq C, Sanchez-Alcaraz MT, Schwartz-Cornil I, Kerkhofs P, Jean G, Théwis A, Hay J, Mortreux F, Wattel E, Reichert M, Burny A, Kettmann R, Bangham C, Willems L. Cell dynamics and immune response to BLV infection: a unifying model. *Front Biosci.* 2007;12:1520–31.
14. Graves DC, Ferrer JF. In vitro transmission and propagation of the bovine leukemia virus in monolayer cell cultures in vitro transmission and propagation of the bovine leukemia virus in monolayer cell cultures. *Cancer Res.* 1976;36:4152–9.
15. Guillemain B, Mamoun R, Levy D, Astier T, Irgens K, Parodi AA. Early polykaryocytosis inhibition: a simple quantitative in vitro assay for the detection of bovine leukemia virus infection in cattle. *Eur J Cancer.* 1978;14:811–27.
16. El Hajj H, Nasr R, Kfoury Y, Dassouki Z, Nasser R, Kchour G, Hermine O, de Thé H, Bazarbachi A. Animal models on HTLV-1 and related viruses: what did we learn. *Front Microbiol.* 2012;3:1–18.
17. Lairmore MD. Animal models of bovine leukemia virus and human T-lymphotrophic virus type-1: insights in transmission and pathogenesis. *Annu Rev Anim Biosci.* 2014;2:189–208.
18. Lomonaco M, Sowul M, Malacari D, Alvarez I, Porta N, Jaworski J, Gutierrez G, Zabal O, Trono K. Pasteurization and the spray-drying heat treatments are effective to inactivate bovine leukemia virus in milk and colostrum. In: 18th international conference on human retroviruses: HTLV and related viruses. 2017.
19. Lomonaco M, Alvarez I, Martínez C, Porta N, Merlini R, Carignano H, Gutiérrez G, Trono K. Epidemiological features of BLV natural infection. In: 16th international conference on human retroviruses: HTLV and related viruses. Suplemento de resúmenes 11. 2014. p. 45.
20. Mammerickx M, Portetelle D, Burny A. Experimental cross-transmissions of bovine leukemia virus (BLV) between several animal species. *Zentralbl Veterinarmed B.* 1981;28:69–81.
21. Mammerickx M, Portetelle D, de Clercq K, Burny A. Experimental transmission of enzootic bovine leukosis to cattle, sheep and goats: infectious doses of blood and incubation period of the disease. *Leuk Res.* 1987;11:353–8.
22. Maresca C, Costarelli S, Dettori A, Felici A, Iscaro C, Feliziani F. Enzootic bovine leukosis: report of eradication and surveillance measures in Italy over an 8-year period (2005–2012). *Prev Vet Med.* 2015;119:222–6.
23. Martínez C, Gutiérrez G, Alvarez I, Porta N, Lomonaco M, Wigdorovitz A, Chacana P, Trono K. Egg yolk antibodies (IgY) against Bovine Leukemia Virus. In: 16th international conference on human retroviruses: HTLV and related viruses. Suplemento de resúmenes 11. 2014. p. 46.
24. Miller J, Miller L, Olson C, Gillette K. Virus-like particles in phytohemagglutinin-stimulated lymphocyte cultures with reference to bovine lymphosarcoma. *J Natl Cancer Inst.* 1969;43:1297–305.
25. Nuotio L, Rusanen H, Sihvonen L, Neuvonen E. Eradication of enzootic bovine leukosis from Finland. *Prev Vet Med.* 2003;59:43–9.
26. Olson C, Kaja R, Burny A, Kettmann R. Goat lymphosarcoma from bovine leukemia virus. *J Natl Cancer Inst.* 1981;67:671–5.
27. Olson C, Baumgartener LE. Pathology of lymphosarcoma in sheep induced with bovine leukemia virus. *Cancer Res.* 1976;36:2365–73.
28. Onuma M, Wada M, Yasutomi Y, Yamamoto M, Okada HM, Kawakami Y. Suppression of immunological responses in rabbits

- experimentally infected with bovine leukemia virus. *Veterinapv Microbiol.* 1990;25:131–41.
29. Pomier C, Alcaraz MTS, Debacq C, Lançon A, Kerkhofs P, Willems L, Wattel E, Mortreux F. Early and transient reverse transcription during primary deltaretroviral infection of sheep. *Retrovirology.* 2008;5:1–12.
  30. Rhodes JK, Pelzer KD, Johnson YJ. Economic implications of bovine leukemia virus infection in mid-Atlantic dairy herds. *J Am Vet Med Assoc.* 2003;223:346–52.
  31. Rodríguez SM, Florins A, Gillet N, de Brogniez A, Sánchez-Alcaraz MT, Boxus M, Boulanger F, Gutiérrez G, Trono K, Alvarez I, Vagnoni L, Willems L. Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV. *Viruses.* 2011;3:1210–48.
  32. Trono KG, Pérez-Filgueira DM, Duffy S, Borca MV, Carrillo C. Seroprevalence of bovine leukemia virus in dairy cattle in Argentina: comparison of sensitivity and specificity of different detection methods. *Vet Microbiol.* 2001;83:235–48.
  33. Van, Miller JM. Replication of bovine leukemia virus in monolayer cell cultures. *Bibl Haematol.* 1975:360–2.
  34. Willems L, Kerkhofs P, Dequiedt F, Portetelle D, Mammerickx M, Burny A, Kettmann R. Attenuation of bovine leukemia virus by deletion of R3 and G4 open reading frames. *Proc Natl Acad Sci U S A.* 1994;91:11532–6.
  35. Willems L, Kettmann R, Burny A, Portetelle D, Kerkhofs P, Attenelle L. The major homology region of bovine leukaemia virus p24gag is required for virus infectivity in vivo. *J Gen Virol.* 1997;78:637–40.
  36. Willems L, Kettmann R, Dequiedt F, Portetelle D, Voneche V, Cornil I, Kerkhofs P, Burny A, Mammerickx M. *In vivo* infection of sheep by bovine leukemia virus mutants. *J Virol.* 1993;67:4078–85.
  37. Williams DL, Amborski GF, Davis WC. Enumeration of T and B lymphocytes in bovine leukemia virus-infected cattle, using monoclonal antibodies. *Am J Vet Res.* 1988;49:1098–103.
  38. Wu D, Murakami K, Morooka A, Jin H, Inoshima Y, Sentsui H. *In vivo* transcription of bovine leukemia virus and bovine immunodeficiency-like virus. *Virus Res.* 2003;97:81–7.
  39. Wyatt CR, Wingett D, White JS, Buck CD, Knowles D, Reeves R, Magnuson NS. Persistent infection of rabbits with bovine leukemia virus associated with development of immune dysfunction. *J Virol.* 1989;63:4498–506.